
Phase 2 Study of Experimental Eosinophilic Gastritis and Eosinophilic Gastroenteritis Drug Yields Encouraging Data
According to a press release from Allakos, the Company's experimental eosinophilic gastritis and eosinophilic gastroenteritis drug candidate AK002 has met all primary and secondary endpoints in a phase 2 study…